

Image

01-16-04

EV394967266US

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.


UAB-15402/22

1614

In Re Application Of: Jay M. Meythaler et al.

Serial No.	Filing Date	Examiner	Group Art Unit
10/049,328	May 15, 2002	Frederick F. Krass	1614

Title: USE OF GABA AGONIST FOR TREATMENT OF SPASTIC DISORDERS, CONVULSIONS, AND EPILEPSY



Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

- ☐ the statement specified in 37 CFR 1.97(e);

OR

- ☒ the fee set forth in 37 CFR 1.17(p).

01/20/2004 HTECKLUI 00000046 10049328

01 FC:1806

180.00 0P

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
UAB-15402/22

In Re Application: Jay M. Meythaler et al.

Serial No.

10/049,328

Filing Date

May 15, 2002


Examiner

Frederick F. Krass

Group Art Unit

1614

USE OF GABA AGONIST FOR TREATMENT OF SPASTIC DISORDERS, CONVULSIONS, AND



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of \$180.00 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 07-1180 as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by ~~First Class~~ ^{EXPRESS} Mail

I certify that this document and fee is being deposited on Jan. 14, 2004 with the U.S. Postal Service as ~~first class mail~~ under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
EXPRESS MAIL # EV394967 266 US

Janice R. Kuehn

Signature of Person Mailing Correspondence

JANICE R. KUEHN

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Avery N. Goldstein

Signature

Dated:

January 13, 2004

Avery N. Goldstein, Reg. No. 39,204

Attorney for Applicant

Gifford, Krass, Groh, Sprinkle,


Anderson & Citkowski, P.C.

280 N. Old Woodward Avenue, Suite 400

Birmingham, MI 48009-5394

(248) 647-6000

CC:



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

UAB-15402/22

Application Number

10/049,328

Applicant(s)

Jay M. Meythaler et al.

Filing Date

May 15, 2002

Group Art Unit

1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Akman et al. "Intrathecal baclofen: does tolerance occur?" Paraplegia 31 (1993) 516-520.

Bergmann. "Progabide: A New GABA-Mimetic Agent in Clinical Use" Clinical Neuropharmacology, Vol. 8, No. 1, pp. 13-26 (1985).

Coffey et al. "Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study" J. Neurosurg., Vol. 78, pp. 226-232 (Feb. 1993).

Klockgether et al. "Myorelaxant effect after intrathecal injection of antispastic drugs in rats" Neuroscience Letters, 97 (1989) 221-226.

Knutsson et al. "Plasma and Cerebrospinal Fluid Levels of Baclofen (Lioresal) at Optimal Therapeutic Responses in Spastic Paresis" Journal of the Neurological Sciences, 23: 473-484 (1974).

Kroin et al. "Reduced Spinal Reflexes Following Intrathecal Baclofen in the Rabbit" Exp. Brain Res. 54: 191-194 (1984).

Lazorthes et al. "Chronic intrathecal baclofen administration for control of severe spasticity" J. Neurosurg. 72: 393-402 (1990).

Meythaler et al. "Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report" J. Neurosurg. 87: 415-419 (1997).

Penn et al. "Intrathecal Baclofen for Severe Spinal Spasticity" The New England Journal of Medicine, Vol. 320, No. 23, pp. 1517-1521 (June 8, 1989).

Sandyk et al. "Baclofen-Induced Memory Impairment" Clinical Neuropharmacology, Vol. 8, No. 3, pp. 294-295 (1985).

Wilson et al. "Baclofen is Antinociceptive in the Spinal Intrathecal Space of Animals" European Journal of Pharmacology 51: 323-330 (1978).

Young et al. "Drug Therapy - Spasticity (First of Two Parts)" The New England Journal of Medicine, Vol. 304, No. 1, pp. 28-33 (Jan. 1, 1981).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Young et al. "Drug Therapy - Spasticity (Second of Two Parts)" The New England Journal of Medicine, Vol. 304, No. 2, pp. 96-99 (Jan. 8, 1981).

DATE CONSIDERED